


Figure 3. Management of Chronic Hepatitis C Virus (HCV) Infection

Diagnosed Chronic HCV Infection

Hepatitis C-Infected Patient, Baseline Panel 1 (91704)
Autoimmune Hepatitis Differential Panel for Hep-C Patient (91705)
Hepatitis C Viral RNA, Quantitative, Real-Time PCR (35645)
Hepatitis C Viral RNA, Genotype, LiPA (37811)
Consider assessing liver fibrosis with biopsy or serum markers (eg, Liver Fibrosis, FibroTest-ActiTest Panel [92688])
Consider AccuType® Ribavirin (*ITPA*) genotype test (91416) to assess risk of ribavirin-associated anemia

Patient is a candidate for treatment and has no contraindications (eg, autoimmune hepatitis)



Serum markers (eg, Liver Fibrosis, FibroTest-ActiTest Panel [92688]) may be helpful in assessing the presence of advanced fibrosis but have limitations that should be taken into account when interpreting results.^{26,27} Patients who are not selected for therapy should continue to be monitored; biopsy may be warranted in those with evidence of progressive liver disease.

This figure was developed by Quest Diagnostics based in part on references 26-28. It is provided for informational purposes only and is not intended as medical advice. A physician's test selection and interpretation, diagnosis, and patient management decisions should be based on his/her education, clinical expertise, current guidelines, and assessment of the patient.